University of Michigan

umich.edu

Matched: University of Michigan Rogel Cancer Center · University of Michigan

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

1,800

Active

296

Phase 3

46

Total enrollment

628,409

Pipeline matrix

Showing 40 of 86 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Acetaminophen3
NSAID2
Opioid2
Paclitaxel13
Dupilumab3
Ibuprofen2
Warfarin2
SGLT2 inhibitor1
Vitamin K1
Imiquimod 5% Topical Cream1
Dapagliflozin 10mg Tab1
Metoprolol Succinate2
Lexapro1
Relugolix CT1
Cyclobenzaprine1
Pembrolizumab9
Mycophenolate Mofetil4
Olaparib3
Temozolomide3
Cyclophosphamide2
Leuprolide2
Prednisone2
Carboplatin17
Sirolimus2
Nivolumab11
Tacrolimus5
Ipilimumab5
Bortezomib4
Ruxolitinib4
Vorinostat3
Methotrexate3
Lenalidomide3
Pacritinib3
Enzalutamide2
ESK9812
Freeze-Dried California Table Grape1
Iron chelation1
Potato Resistant Starch1
AZD67381
Tirzepatide1
46 more active programs hidden

Next readouts

  • 2023-01-26
  • 2024-04-08
  • 2024-05-02
  • 2025-01-06
  • 2025-01-08
  • 2025-07-30
  • 2026-01-19
  • 2026-02-21
  • 2026-05-02
  • 2026-06-30

Top conditions

  • Depression52
  • Breast Cancer50
  • Healthy39
  • Prostate Cancer38
  • Obesity28
  • Hypertension23
  • Anxiety21
  • Chronic Pain19

Frequently asked questions about University of Michigan

How many clinical trials does University of Michigan have on ClinicalTrials.gov?
University of Michigan is listed as the lead sponsor on 1,800 clinical trials in ClinicalTrials.gov, 296 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Michigan's trials are in Phase 3?
46 of University of Michigan's trials are in Phase 3, spread across 86 active drug programs.
What therapeutic areas does University of Michigan focus on?
University of Michigan's most-studied conditions on ClinicalTrials.gov are Depression, Breast Cancer, Healthy, Prostate Cancer, Obesity.
When are University of Michigan's next clinical trial readouts?
University of Michigan has 10 upcoming primary-completion readouts tracked here; the soonest is “Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)”, expected around 2023-01-26.